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Abstract
Objective To compare autoantibody features in patients
with primary biliary cirrhosis (PBC) and individuals pre-
senting antimitochondria antibodies (AMAs) but no clini-
cal or biochemical evidence of disease.
Methods A total of 212 AMA-positive serum samples were
classified into four groups: PBC (definite PBC, n = 93);
PBC/autoimmune disease (AID; PBC plus other AID,
n = 37); biochemically normal (BN) individuals (n = 61);
and BN/AID (BN plus other AID, n = 21). Samples were
tested by indirect immunofluorescence (IIF) on rat kidney
(IIF-AMA) and ELISA [antibodies to pyruvate dehydroge-
nase E2-complex (PDC-E2), gp-210, Sp-100, and CENP-A/B].
AMA isotype was determined by IIF-AMA. Affinity of
anti-PDC-E2 IgG was determined by 8 M urea-modified
ELISA.
Results High-titer IIF-AMA was more frequent in PBC and
PBC/AID (57 and 70 %) than in BN and BN/AID samples
(23 and 19 %) (p \ 0.001). Triple isotype IIF-AMA (IgA/
IgM/IgG) was more frequent in PBC and PBC/AID samples
(35 and 43 %) than in BN sample (18 %; p = 0.008;
p = 0.013, respectively). Anti-PDC-E2 levels were higher
in PBC (mean 3.82; 95 % CI 3.36–4.29) and PBC/AID
samples (3.89; 3.15–4.63) than in BN (2.43; 1.92–2.94)
and BN/AID samples (2.52; 1.54–3.50) (p \ 0.001). Anti-
PDC-E2 avidity was higher in PBC (mean 64.5 %; 95 %
CI 57.5–71.5 %) and PBC/AID samples (66.1 %;
54.4–77.8 %) than in BN samples (39.2 %; 30.9–37.5 %)
(p \ 0.001). PBC and PBC/AID recognized more cell
domains (mitochondria, nuclear envelope, PML/sp-100
bodies, centromere) than BN (p = 0.008) and BN/AID
samples (p = 0.002). Three variables were independently
associated with established PBC: high-avidity anti-PDC-E2
(OR 4.121; 95 % CI 2.118–8.019); high-titer IIF-AMA (OR
4.890; 2.319–10.314); antibodies to three or more antigenic
cell domains (OR 9.414; 1.924–46.060).
Conclusion The autoantibody profile was quantitatively
and qualitatively more robust in definite PBC as compared
with AMA-positive biochemically normal individuals.
Keywords Autoimmunity  Antibody affinity 
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Introduction
Autoantibodies are hallmarks of autoimmune diseases
(AIDs), and disease-specific autoantibodies are valuable
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diagnostic tools [1]. Primary biliary cirrhosis (PBC) is an
autoimmune liver disease involving predominantly intrahe-
patic biliary duct epithelial cells [2]. Antimitochondria
antibodies (AMAs) are detected in roughly 95 % of PBC
patients, with a specificity of at least 98 % [3, 4]. AMAs are
directed to components of the inner mitochondrial multien-
zyme 2-oxoacid dehydrogenase complex (2-OADC) impli-
cated in the mitochondrial respiratory chain [5]. The E2
subunit of pyruvate DC (PDC-E2) is the main antigenic
moiety in 2-OADC [6]. One-third of PBC patients present a
positive result in the antinuclear antibody (ANA) indirect
immunofluorescence (IIF) assay on HEp-2 cells (ANA-HEp-
2). Two autoantibodies detected in the ANA-HEp-2 assay
appear to be specific for PBC and are observed in approxi-
mately 25 % of the patients. Anti-gp210 antibodies recog-
nize a nuclear pore glycoprotein [7] and anti-Sp-100
antibodies recognize a 53-kDa protein restricted to the pro-
myelocytic leukemia (PML) nuclear bodies [8]. Anticen-
tromere antibodies have also been observed in PBC, with an
apparent association with portal hypertension [9, 10].
The ANA-HEp-2 test is the standard screening assay for
autoantibodies [11], and the immunofluorescence pattern in
a positive ANA-HEp-2 test may indicate the possible
autoantibody specificities present in a given sample [11–13].
AMA yields a peculiar cytoplasm pattern in the ANA-HEp-
2 assay (Fig. 1). By processing roughly 323,000 samples in
the ANA-HEp-2 assay in a time frame of 8 years, we
identified a considerable number of samples with the
characteristic AMA-like cytoplasm pattern (Fig. 1). Pro-
cessing such samples in AMA-specific assays eventually
resulted in a sizable number of AMA-positive asymptom-
atic individuals with normal liver enzyme serum levels
(Fig. 1). The significance of such AMA response in
apparently normal individuals is unknown. Neither is
it known how this immune response compares with the
autoimmune response observed in clinically established
PBC?
The intrinsic features of any given humoral response are
quite heterogeneous with respect to titer, avidity, and
immunoglobulin isotype of the antibodies, as well as the
ANA-HEp-2 from 2002 to 2010 323,626 samples
Positive samples  133,434 (41.2%) 
Cytoplasm pattern  9,764 (7.3%) No cytoplasm pattern  123,670 (92.7%) 
Mitochondria-like cytoplasm 
pattern  2,271 (23.2%)
Anti-mitochondria antibody (AMA) assays 
IIF-AMA
Anti-PDC-E2 ELISA
WB-AMA
Negative in all 
AMA-assays 
Positive in at 
least one AMA-
assay 
PBC  69 (45.7%) 
Individuals with normal liver enzyme and no evidence for PBC  82 (54.3%) 
Excluded from 
the study 
Included in the 
study (n 151) 
Samples with good amount of 
serum and available clinical 
information 270 (11.9%)
Fig. 1 Algorithm for selection
of samples according to the
identification of the peculiar
cytoplasm mitochondria-like
pattern in the antinuclear
antibody (ANA) indirect
immunofluorescence (IIF) assay
on HEp-2 cells assay
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spectrum of targeted antigens and epitopes. In the present
study we investigated AMA serum levels, AMA isotypes,
and the avidity and serum levels of anti-PDC-E2 IgG
antibodies in PBC patients and in AMA-positive asymp-
tomatic and biochemically normal individuals. Reactivity
against other mitochondrial antigens and the serum levels
of antibodies to gp210, Sp-100, and the centromere pro-
teins CENP-A and CENP-B were also investigated.
Materials and methods
The 212 AMA-positive samples used in the present study
were derived from two sources: 61 (28.7 %) samples from
patients with definite PBC attending at the Hepatology
Division of Sao Paulo University School of Medicine and
151 (71.2 %) samples selected from the ANA-HEp-2 daily
operation from January 2002 to January 2010 at Fleury
Medicine and Health Laboratories (certified on-site by the
College of American Pathologists/CAP). Throughout these
8 years, 323,626 samples were processed for ANA-HEp-2.
Samples were suspected to be AMA-positive because of the
AMA-like pattern in the ANA-HEp-2 assay (Fig. 1). Those
confirmed to be AMA-positive on specific assays (IIF on
rodent tissue, ELISA, or Western blot) were selected for the
present study. Clinical data were obtained by chart review
and interview with the physicians who ordered the tests. PBC
diagnosis was established according to the American Asso-
ciation for Study of Liver Diseases criteria [14]. For most
patients consistently increased alkaline phosphatase serum
levels and AMA were enough to establish PBC diagnosis.
Some patients required liver biopsy for confirmation.
Whenever appropriate, image studies were undertaken to
rule out the possibility of biliary tract obstruction. Serum
liver enzymes were determined in all samples of patients
without definite PBC diagnosis. Samples were classified into
four groups: PBC group (n = 93)—definite PBC according
to established diagnostic criteria [14]; PBC/AID group
(n = 37)—definite PBC plus any nonhepatic AID; bio-
chemically normal (BN) group (n = 61)—individuals with
no apparent disease and normal alkaline phosphatase serum
levels; and BN/AID group (n = 21)—BN plus any nonhe-
patic AID. BN and BN/AID individuals had at least two
samples separated by at least 6 months with normal alkaline
phosphatase levels. Samples with slightly elevated alkaline
phosphatase serum levels (less than twofold the upper nor-
mal limit) and no further evidence of PBC were excluded
from the present study. Samples were processed without the
knowledge of their identity and the group to which they
belonged. The study was approved by the National Com-
mittee for Ethics in Research (CONEP).
AMA was determined by IIF (IIF-AMA) and ELISA.
IIF-AMA on in-house rodent tissue preparations was
performed as described elsewhere [15]. Samples were
screened at 1:40 and serially diluted up to end-point fluores-
cence or to 1:2,560. Positive samples were tested for AMA
isotype with fluorescein isothiocyanate (FITC)-conjugated
goat antibodies against human IgG (BioMe´rieux, Marcy
l’Etoile, France), IgM and IgA (Dako, Bucks, UK) at 1:200
(anti-IgG and anti-IgM) and 1:20 (anti-IgA). ANA-HEp-2
was performed at 1:160 in HEp-2 cell slides (Bion, Des
Plaines, IL, USA) following the manufacturer’s instructions.
In addition to the characteristic cytoplasm mitochondria-like
pattern, we registered the occurrence of reactivity to the
nuclear envelope, multiple nuclear dots, and centromere.
Slides were independently analyzed by two blinded readers
(AD and LECA) using an Olympus B50 fluorescence micro-
scope (Center Valley, PA USA) at 9400 magnification.
Reactivity against purified gp210 and Sp-100, and
recombinant CENP-A/B was determined by ELISA
(INOVA Diagnostics), according to the manufacturer’s
instructions. Antibodies against PDC-E2 (M2 fraction)
were determined by ELISA (Orgentec, Mainz, Germany)
according to the manufacturer’s instructions. The affinity
of anti-PDC-E2 IgG was determined under chaotropic
conditions [16]. Samples were incubated in quadruplicate
in the standard anti-PDC-E2 ELISA for 1 h. Next, for each
quadruplicate set, two wells were incubated with regular
washing solution and two wells were incubated with urea
8 M in PBS-T for 15 min at room temperature. Plates were
then washed and further processed as per the regular
ELISA. Affinity was estimated by dividing the optical
density observed in the wells submitted to urea treatment
by the optical density of wells without urea treatment.
IgG reactivity against individual 2-OADC antigens [E2
subunits of PDC-E2/74 kDa, BCOADC (56 kDa), OGDC
(52 kDa), and the E3BP (36 kDa), E1alpha (48 kDa),
E1-beta subunits (41 kDa)] was determined by Western
blot (WB) [17–19]. Briefly, mitochondria-rich liver extract
(10 mg/mL) was separated by 10 % sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis and transferred
onto nitrocellulose filters. After blocking in PBS containing
5 % skim milk for 2 h, longitudinal strips were incubated
with individual serum samples diluted 1:50 in blocking
solution for 1 h. Strips were then washed three times in
PBS-T and incubated for 1 h at room temperature in
horseradish peroxidase-conjugated rabbit anti-human IgG
1:1,500 (Bio-Rad, Hercules, CA, USA) in blocking solu-
tion. After washing in PBS-T, the colorimetric reaction was
developed for 10 min in 6 mg 4-chloro-1-naphthol diluted
in 2 mL methanol added to 10 mL PBS containing 20 lL
30 % H2O2. The reaction was stopped with distilled water
after the development of bands.
Categorical variables were analyzed by the Chi-square
test. Kruskal–Wallis and Mann–Whitney tests were used to
compare quantitative and semiquantitative nonparametric
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variables. Multiple regression analysis was used to identify
variables independently associated with the classification
as definite PBC. The nomogram model was used to cal-
culate the interaction of the independent variables. A
p value of less than 0.05 was considered significant.
Results
The majority of individuals were females (90.6 %), and
there was no significant difference in gender and age dis-
tribution among the four groups (Table 1). Information on
current liver enzyme serum levels was available for all BN
and BN/AID subjects, but not for all PBC and PBC/AID
patients. Increased alkaline phosphatase serum levels were
observed at the time of the study in 37 % of PBC patients
and in 25 % of PBC/AID patients. Normal alkaline phos-
phatase levels in PBC and PBC/AID groups were because
of ursodeoxycholic acid therapy, which was used in the
majority of these patients (Table 1). Liver biopsy infor-
mation was available for one-quarter of PBC patients and
half of PBC/AID patients, most of whom exhibited lesions
compatible with stages II and III (Table 1).
IIF-AMA was positive in 94.3 % (200/212) of the
samples (Table 2) and the remaining 12 samples were
reactive in PDC-E2 ELISA or WB-AMA. IIF-AMA fre-
quency was slightly lower in the BN/AID group
(p = 0.021). IIF-AMA titers were arbitrarily divided into
low (1:40–1:80), medium (1:160–1:320), and high strata
(1:640–1:2,560). High titer IIF-AMA was associated with
PBC and PBC/AID groups, whereas low titer IIF-AMA
was associated with BN and BN/AID groups (Fig. 2a). In
Table 1 Demographic and clinical characteristics of the 212 studied individuals
Parameters Groups
PBC (n = 93) PBC/AID (n = 37) BN (n = 61) BN/AID (n = 21)
No. of females* (%) 84 (90.3 %) 32 (86.5 %) 57 (93.4 %) 19 (90.5 %)
Age (years)**,a 54.2 (29–85) 51.6 (31–73) 51.5 (26–84) 49.5 (18–68)
Biochemistry and therapeutics
Alkaline phosphatasea 229 (52–776) 231 (117–385) 67 (32–115) 59 (16–99)
Increased alkaline phosphatase 23/61 (37.7 %) 2/8 (25 %) 0/61 0/21
Ursodeoxycholic acidb 65/85 (76.4 %) 30/36 (83.3 %) 0/61 0/21
Liver biopsy
Biopsy available 25/93 (26.8 %) 21/37 (56.7 %) Not applicable
Stage I 2/25 (8 %) 2/21 (9.5 %)
Stage II 5/25 (20 %) 7/21 (33.3 %)
Stage III 11/25 (44 %) 8/21 (38 %)
Stage IV 4/25 (16 %) 3/21 (14.2 %)
Nonconclusive 3/25 (12 %) 1/21 (4.7 %)
Associated diseases
CREST 0 7 (19 %) 0 0
Systemic sclerosis 0 1 (2.7 %) 0 1 (4.7 %)
Sjo¨gren’s syndrome 0 12 (32.4 %) 0 2 (9.5 %)
Rheumatoid arthritis 0 4 (10.8 %) 0 2 (9.5 %)
Celiac disease 0 4 (10.8 %) 0 0
SLE 0 1 (2.7 %) 0 0
Thyroid disease 0 2 (5.4 %) 0 2 (9.5 %)
Miscellaneousc 0 12 (32.4 %) 0 16 (76.1 %)
Reference values for alkaline phosphatase (female 35–104 U/mL, male 40–129 U/mL)
BN biochemically normal individuals, BN/AID biochemically normal individuals with some other autoimmune disease, PBC primary biliary
cirrhosis, PBC/AID primary biliary cirrhosis plus other autoimmune disease, SLE systemic lupus erythematosus
* p = 0.725; ** p = 0.383
a Mean and range
b Number of patients receiving ursodeoxycholic acid over the number of patients with information about therapeutic regimen
c Miscellaneous: psoriasis, pulmonary vasculitis, polymyositis, pemphigus, autoimmune retinitis, renal tubular acidosis, Raynaud phenomenon,
temporal arteritis, polymyalgia rheumatica, psoriatic arthritis, seronegative polyarthritis, colon diverticulitis, isolated sacroiliitis, non-specific
muscle-skeletal pain, pernicious anemia, idiopathic trombocytopenic purpura
778 Hepatol Int (2013) 7:775–784
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addition, there were some differences in IIF-AMA isotype
among the groups (Table 2). All IIF-AMA-positive sam-
ples had the IgG isotype. IgM IIF-AMA was more frequent
in PBC and PBC/AID than in the BN group (p = 0.003 and
p = 0.004, respectively). IgA IIF-AMA was also more
frequent in PBC and PBC/AID than in the BN group
(p = 0.023 and p = 0.007, respectively). Finally, PBC and
PBC/AID had a higher frequency of samples with triple
isotype IIF-AMA than the BN group (p = 0.013 and
p = 0.008, respectively) (Table 2; Fig. 2b).
The four groups were equivalent in the frequency of
positive samples for anti-PDC-E2 (Table 2). However,
Table 2 Distribution of AMA-positive samples of primary biliary cirrhosis patients and biochemically normal individuals according to the
reactivity in multiple assays for autoantibodies
BN biochemically normal individuals, BN/AID biochemically normal individuals with some other autoimmune disease, PBC primary biliary
cirrhosis, PBC/AID primary biliary cirrhosis plus other autoimmune disease
a BN/AID 9 PBC (p = 0.021)
b PBC 9 BN (p = 0.003); PBC/AID 9 BN (p = 0.004)
c PBC 9 BN (p = 0.023); PBC/AID 9 BN (p = 0.007)
d 1 isotype: BN 9 PBC (p = 0.006) and BN 9 PBC/AID (p = 0.003); 3 isotypes: PBC 9 BN (p = 0.013) and PBC/AID 9 BN (p = 0.008)
e BN 9 PBC (p = 0.019) and BN 9 PBC/AID (p = 0.048)
f PBC 9 BN (p = 0.004)
g PBC/AID 9 PBC (p = 0.014); PBC/AID 9 BN (p \ 0.001); PBC/AID 9 BN/AID (p = 0.021)
h 1 cellular target: BN/AID 9 PBC/AID (p = 0.008); BN 9 PBC/AID (p = 0.003); C3 cellular targets PBC/AID 9 BN (p \ 0.001);
PBC/AID 9 BN/AID (p = 0.005); PBC 9 BN (p = 0.048)
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PBC and PBC/AID groups presented higher serum levels
of anti-PDC-E2 antibodies than BN and BN/AID groups
(Fig. 3a). There was no difference in serum levels of anti-
PDC-E2 antibodies between PBC and PBC/AID, and
between BN and BN/AID groups. Receiver operating curve
(ROC) analysis indicated that the best anti-PDC-E2 serum
level to discriminate PBC and PBC/AID from BN and BN/
IAD groups was 3.0 IU/mL (Fig. 3c). The avidity of anti-
PDC-E2 IgG was determined in all anti-PDC-E2-reactive
samples (170/212) and was found to be significantly higher
in PBC and PBC/AID than in the BN group (Fig. 3b). The
best anti-PDC-E2 IgG avidity level to discriminate PBC
and PBC/AID from BN and BN/IAD groups was 64 %
(Fig. 3d). WB also showed some differences among the
four groups (Table 2). The BN group had a lower fre-
quency of reactive samples than PBC (p = 0.019) and
PBC/AID (p = 0.048) groups. In addition, the PBC group
presented a higher frequency of 74-kDa reactive samples
than the BN group (p = 0.004) (Table 2).
Concerning the ANA-HEp-2 patterns indicative of spe-
cific cell domains (centromeres, nuclear envelope, and PML
bodies), the centromere pattern was significantly more fre-
quent in PBC/AID samples than in PBC (p = 0.014), BN
(p \ 0.001), and BN/AID samples (p = 0.021) (Table 2).
Anti-CENP-A/B antibodies were detected in 31 of the 212
samples with a higher frequency in PBC/AID (14/37;
37.9 %) than in PBC (14/93; 15.1 %; p = 0.009), BN (2/61;
3.3 %; p \ 0.001), and BN/AID groups (1/21; 4.8 %;
p = 0.014). Anti-CENP-A/B antibodies presented higher
serum levels in PBC/AID than in PBC (p = 0.006), BN
(p \ 0.001), and BN/AID samples (p = 0.030) (Fig. 4a).
The 14 PBC/AID patients with anticentromere antibodies
had varied diagnoses (41.6 % CREST syndrome, 33.3 %
Sjo¨gren syndrome, 16.6 % Raynaud syndrome, and 8.3 %
celiac disease), for which the very presence of anticentro-
mere antibodies was not a driving diagnostic criterion. There
was no significant difference regarding other ANA-HEp-2
patterns among the four groups (p = 0.248) (Table 2).
However, the number of cell antigenic domains (mitochon-
dria, nuclear envelope, PML/Sp-100 domain, and centro-
mere) recognized per individual sample differed among the
four groups (p = 0.005). PBC and PBC/AID groups pre-
sented a higher frequency of samples recognizing three or
more targets as compared with BN (p = 0.048 and\0.001,
respectively) (Table 2; Fig. 2c).
The frequency of anti-gp210 antibodies was equivalent
among the four groups but anti-gp210 serum levels were
higher in PBC and PBC/AID groups (Fig. 4b). In fact, anti-
gp210 levels above 100 AU/mL were observed in 16
(12.9 %) of the PBC and PBC/AID samples but only 1
(1.2 %) of the BN and BN/AID samples (p = 0.0032).
Anti-Sp-100 antibodies showed a similar frequency in all
samples presenting any definite nuclear fluorescence in the
ANA-HEp-2 test [PBC: 23 of 53 (43.4 %); PBC/AID: 12
of 24 (50 %); BN: 13 of 30 (43.3 %); and BN/AID: 4 of 10
(40 %)] (p = 0.808). There was no difference in serum
levels of anti-Sp-100 antibodies among the four groups
(Fig. 4c).
Several serological parameters presented a significant
association with the current classification of samples as
belonging to patients with definite PBC (Table 3), includ-
ing high titer IIF-AMA, triple isotype IIF-AMA, high titer
and high avidity anti-PDC-E2 antibodies, and three or more
cellular domains recognized by autoantibodies. Multiple
regression analysis identified three independent variables
presenting a significant association with definite PBC: high
PanelB: “0 isotype” “Negative”
PanelsA & B: “AMA IIF” “IIF AMA”
IIF-AMA titer
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Fig. 2 Distribution of samples according to a indirect immunofluo-
rescence (IIF) on rat kidney (IIF-AMA) titer (p \ 0.001), b number of
IIF-AMA isotypes (p = 0.005), c number of antigenic cellular
domains targeted (p = 0.005). BN, AMA-reactive individuals with
normal levels of alkaline phosphatase; BN/AID, same as BN but with
any associated extrahepatic autoimmune disease; PBC, definite
primary biliary cirrhosis; PBC/AID, definite primary biliary cirrhosis
and any associated extrahepatic autoimmune disease
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avidity anti-PDC-E2 antibodies (OR 4.12; 95 % CI
2.12–8.02), high titer IIF-AMA antibodies (OR 4.89; 95 %
CI 2.32–10.31), and three or more cell domains recognized
by autoantibodies (OR 9.41; 95 % CI 1.92–46.06). These
three independent variables interact with each other to
further increase the probability of a current diagnosis of
PBC (Table 4).
Discussion
The present study disclosed several differences in the
intrinsic features of the autoantibody profile in individuals
with AMA reactivity and normal levels of alkaline phos-
phatase as opposed to patients with definite PBC. Patients
with definite PBC displayed a more vigorous autoantibody
profile, represented by higher serum levels of IIF-AMA, a
higher frequency of triple isotype IIF-AMA, higher serum
levels and higher avidity anti-PDC-E2 IgG, and higher titer
anti-gp210 antibodies. In addition, the autoantibody profile
in patients with definite PBC addressed a broader set of
antigenic targets, recognizing a higher number of cell
domains than individuals with no biochemical or clinical
evidence of PBC. These differences were true regardless of
the presence of an associated extrahepatic AID. Multiple
regression analysis identified three independent risk factors
for the classification of a sample as belonging to bio-
chemically normal individuals or to patients with definite
PBC, namely high titer IIF-AMA, high avidity anti-PDC-
E2 antibodies, and widespread reactivity against multiple
cell domains. This observation might be clinically useful in
the instance of an unexpected positive AMA result in an
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Fig. 3 Distribution of samples according to a titer concentration (IU/
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IgG (p \ 0.001). Receiver operating curve analysis comparing PBC
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c titer concentration (IU/mL) of anti-E2-PDC IgG [AUC = 0.679
(95 % CI 0.606–0.751)] and d avidity of anti-E2-PDC IgG
[AUC = 0.704 (95 % CI 0.633–0.755)]. BN, AMA-reactive asymp-
tomatic individuals with normal levels of alkaline phosphatase; BN/
AID, same as BN but with any associated extrahepatic autoimmune
disease; PBC, definite primary biliary cirrhosis; PBC/AID, definite
primary biliary cirrhosis and any associated extrahepatic autoimmune
disease
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individual with no clinical and biochemical evidence for
PBC. Obviously, these findings must be confirmed by
similar studies in independent series of AMA-reactive
biochemically normal samples and by longitudinal studies
comparing AMA-positive samples before and after the
development of liver involvement.
What is the exact clinical situation of AMA-positive
asymptomatic individuals with normal alkaline phospha-
tase levels? Could they represent preclinical stages of
PBC? Could they represent normal individuals with no
relationship with the PBC disease spectrum? Because of
the design of the present study and the setting in which
samples were obtained, one can determine that they had no
clinical or biochemical evidence of PBC at the moment of
the study. However, we cannot rule out the possibility that
some of them had varied degrees of histological biliary
tract involvement typical of PBC and therefore represented
preclinical stages of histopathologically established dis-
ease. Regardless of the histological status, it is reasonable
to admit that some of these individuals will eventually
develop definite PBC. In fact, previous follow-up studies of
AMA-positive asymptomatic cohorts have shown that a
significant proportion of individuals will develop overt
disease within a variable time interval [14, 19]. In this
context, it is relevant to consider that the 82 AMA-positive
and biochemically normal individuals represent 0.02 % of
323,000 individuals screened. This frequency is not far
from the estimated prevalence of PBC in the general
population [14]. However, because of the cross-sectional
design of the present study we cannot determine the frac-
tion of these individuals who will eventually develop overt
PBC. With these restrictions in mind we may consider that
these individuals might represent a heterogeneous group,
comprising potential patients at preclinical stages of PBC
and normal subjects with no relationship to PBC. Overall,
the obtained data are quite provocative because they shed
some light onto the nature of the autoimmune response at
very early stages of PBC.
It is well established that disease-specific autoantibodies
frequently precede the onset of symptoms and the diag-
nosis of the cognate diseases for months or years. Exam-
ples of such include antinative DNA antibodies and
systemic lupus erythematosus [20], anticitrullinated pep-
tide antibodies or rheumatoid factor and rheumatoid
arthritis [21], antithyroid peroxidase antibodies and Ha-
shimoto thyroiditis [22], anti-insulin antibodies and type I
diabetes mellitus [23], and AMAs and PBC [24]. The
consistent demonstration of disease-specific autoantibodies
preceding the clinical onset of diverse AIDs seems to
indicate that immunological disturbances regularly precede
the establishment of overt disease for a variably long pre-
clinical period in which no or very low inflammatory
activity is present at the target tissues. Understanding the
immunology of such ‘‘pre/low-inflammatory’’ stages of
AIDs may allow the development of effective immuno-
modulatory therapy to successfully prevent the full devel-
opment of such illnesses. An initial approach to study the
immunology of the ‘‘pre/low-inflammatory’’ stages of
AIDs is to analyze the intrinsic features of autoantibodies
before and after their clinical onset. PBC appears to be an
appropriate model for this objective because its natural
history comprises a long period in which circulating
autoantibodies are detected in the absence of clinical and
biochemical events [25]. The relationship between this
particular autoimmune response and the etiology of PBC as
Fig. 4 Distribution of samples according to results of ELISA tests.
a Anti-CENP-A/B antibody serum levels presented higher values in
PBC/AID samples as compared with PBC (p = 0.006), BN
(p \ 0.001), and BN/AID samples (p = 0.030). b Anti-gp210 anti-
body serum levels were higher in PBC and PBC/AID groups as
compared with that in BN and BN/AID groups (p = 0.0032). c Anti-
Sp-100 antibody serum levels showed no difference among the groups
of samples (p = 0.808). BN, AMA-reactive asymptomatic individu-
als with normal levels of alkaline phosphatase; BN/AID, same as BN
but with any associated extrahepatic autoimmune disease; PBC,
definite primary biliary cirrhosis; PBC/AID, definite primary biliary
cirrhosis and any associated extrahepatic autoimmune disease
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well as the precise mechanisms of bile duct destruction
remains unclear, and some authors believe that autoanti-
bodies represent an epiphenomenon not directly related to
the disease pathophysiology. The findings of the present
study suggest that along the transition from early to later
stages of PBC there are marked qualitative and quantitative
changes in the autoantibody profile represented by a higher
rate of production and higher avidity of AMA, as well as
the spreading of antigenic targets recognizing several cell
domains. Although the methodological restrictions of the
present study preclude definite conclusions, these pre-
liminary findings encourage follow-up studies to determine
the longitudinal behavior of the humoral autoimmune
response along the transition from early to later stages of
PBC.
In summary, the present study has provided evidence for
marked qualitative and quantitative differences in the
autoantibody profile of AMA-positive individuals with
normal alkaline phosphatase levels and patients with
established PBC. The present data indicate that high titer
AMA, high avidity anti-PDC-E2 antibodies, and wide-
spread response to multiple cell domains represent risk
factors for a given AMA-positive sample to be associated
with definite PBC. This is an original finding that may shed
some light onto the understanding of the obscure immu-
nological abnormalities preceding the instatement of the
full-blown inflammatory stage of PBC and other AIDs.
Studies on patients with different PBC histological stages
and AMA-positive individuals with no biochemical or
histological evidence of liver disease are required to vali-
date these preliminary results.
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